Gerelma V. Andrenova
Research Subjects
Research Interests
Gerelma V. Andrenova has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Daria Sergeevna Fomina
Center of Allergy and Immunology Clinical Moscow City Hospital 52; The First Sechenov Moscow State Medical University (Sechenov University); Astana Medical University
8 shared publications - Mariana A. Lysenko
Moscow Clinical Science and Research Center Hospital No. 52; The Russian National Research Medical University named after N.I. Pirogov
6 shared publications - Alexander Viktorovich Karaulov
Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
5 shared publications - Marina S. Lebedkina
Moscow Research and Clinical Center of Allergy and Immunology, Moscow Healthcare Department City Clinical Hospital Moscow Russia
5 shared publications - Tatyana S. Kruglova
Moscow City Hospital 52
5 shared publications - Anton A. Chernov
City Clinical Hospital No. 52
4 shared publications
Latest Publications
- 27 August 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (4) , 422-431
Still’s disease in a patient with common variable immunodeficiency: NFKB1 defect
Сommon variable immunodeficiency is the most prevalent form of inborn errors of immunity, however, genetic cause may be identified in less than a third of the cases. Pathogenic variants in the subunit 1 of nuclear factor κB are thought to be one of the most frequent monogenic causes of common variable immunodeficiency. Besides the humoral immunodeficiency, NFKB1 defect is characterized by a wide range of autoimmune, autoinflammatory and hematological features. To date, there are no standardized guidelines for immunosuppressive or anti-inflammatory therapy in patients with NFKB1 deficiency. We report on a 62 year old woman with common variable immunodeficiency due to heterozygous mutation in the NFKB1 gene, complicated by a systemic form of Still’s disease. Since initiation of the anti-cytokine therapy with the interleukin 6 antagonist olokizumab, resolution of constitutional symptoms has been achieved. Over the 1.5-years follow-up there has been an improvement on lymphadenopathy and joint syndrome according to computed tomography scan and ultrasound. Variety of manifestations of immune disregulation in complex of symptoms of NFKB1 defect forces a neccessity of awareness of the specialists and requires a multidisciplinary approach to selection of an optimal tactic to patient treatment.
- 27 August 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (4) , 422-431
Still’s disease in a patient with common variable immunodeficiency: NFKB1 defect
Сommon variable immunodeficiency is the most prevalent form of inborn errors of immunity, however, genetic cause may be identified in less than a third of the cases. Pathogenic variants in the subunit 1 of nuclear factor κB are thought to be one of the most frequent monogenic causes of common variable immunodeficiency. Besides the humoral immunodeficiency, NFKB1 defect is characterized by a wide range of autoimmune, autoinflammatory and hematological features. To date, there are no standardized guidelines for immunosuppressive or anti-inflammatory therapy in patients with NFKB1 deficiency. We report on a 62 year old woman with common variable immunodeficiency due to heterozygous mutation in the NFKB1 gene, complicated by a systemic form of Still’s disease. Since initiation of the anti-cytokine therapy with the interleukin 6 antagonist olokizumab, resolution of constitutional symptoms has been achieved. Over the 1.5-years follow-up there has been an improvement on lymphadenopathy and joint syndrome according to computed tomography scan and ultrasound. Variety of manifestations of immune disregulation in complex of symptoms of NFKB1 defect forces a neccessity of awareness of the specialists and requires a multidisciplinary approach to selection of an optimal tactic to patient treatment.
- 23 July 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (1)
Mucosal angioedema involving the oropharynx signals severe cold urticaria: COLD ‐ CE study insights
- 23 July 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (1)
Mucosal angioedema involving the oropharynx signals severe cold urticaria: COLD ‐ CE study insights
- Open Access
- 3 June 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (2) , 135-152
ASIA syndrome masked as recurrent angioedema: сan development be predicted by genetic screening (pilot study)
BACKGROUND: ASIA is an autoimmune/inflammatory syndrome induced by adjuvants. Symptoms can be diverse, and the recurrent angioedema is one of the dominant manifestations. Genetic screening is discussed as a preventive option. The following alleles of genes: HLA type II (DRB1*0301 or in combination with HLA-B*08, DRB1*01, and DRB4), as well as Arg620Trp polymorphism in the PTPN22 gene are discussed as a cause of autoimmune diseases, including ASIA syndrome. AIM: To identify the presence of causative genetic factors in patients with ASIA syndrome by genetic screening, to identify adjuvants acting as a trigger, and to evaluate the efficacy of current therapy. MATERIALS AND METHODS: A single center observational study of 16 patients with ASIA syndrome and 10 controls was performed. Genetic screening was performed in 14 patients from the ASIA group and 10 patients from the control group. Further inclusion of patients in the study is planned. RESULTS: All patients with ASIA were women, potential triggers included hyaluronic acid fillers 10/16 (62.5 %), including in combination with breast silicone implants 1/16 (6.25 %), arthroplasty with shoulder joint replacement 1/16 (6.25 %), face hyaluronic acid injections 5/16 (31.25 %), and calcium hydroxyapatite 1/16 (6.25 %). The main site of angioedema was the face 15/16 (93.75 %), also larynx (1/16 (6.25 %)), upper (2/16) and lower extremities (1/16 (6,25 %)). Other symptoms included arthralgia, myalgia, muscle weakness — 1/16 (6.25%), hypocomplementemic urticarial vasculitis, lymphocytic colitis — 1/16 (6.25 %), arthralgia combined with lymphadenopathy — 1/16 (6.25 %), chronic spontaneous and solar urticaria — 1/16 (6.25 %), fixed erythema of the shoulder skin with fever, antiphospholipid syndrome — 1/16 (6.25 %), normocomplementemic urticarial vasculitis — 1/16 (6.25 %), Still’s disease — 1/16 (6.25 %). Autoimmune response was represented by autoantibodies in 10 (62.5 %) of 16 patients. Ten (62.5 %) patients received non-sedative antihistamines at standard and escalated doses (5 as monotherapy, 1 in combination with filler removal, 1 with hydroxychloroquine, 3 with hydroxychloroquine and omalizumab), 1 (6.25 %) received tranexamic acid, 1 (6.25 %) with danazol, 1 (6.25 %) with hydroxychloroquine, and 3 (18.75 %) patients received no therapy. A combination of two genetic factors was detected in 3 (21.4 %) patients: DRB1*0301, B1*08 (in 2 patients additionally Arg620Trp polymorphism). Isolated Arg620Trp polymorphism was detected in 6 (42.8 %) patients. CONCLUSION: Genetic factors increasing the risk of autoimmune conditions were found in 9 out of 16 patients. No genetic abnormalities were found in the control group. More than half of the patients with ASIA syndrome had genetic factors associated with autoimmunity. Further studies are needed to create reliable diagnostic and treatment algorithms.
- 3 June 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (2) , 135-152
Open AccessASIA syndrome masked as recurrent angioedema: сan development be predicted by genetic screening (pilot study)
BACKGROUND: ASIA is an autoimmune/inflammatory syndrome induced by adjuvants. Symptoms can be diverse, and the recurrent angioedema is one of the dominant manifestations. Genetic screening is discussed as a preventive option. The following alleles of genes: HLA type II (DRB1*0301 or in combination with HLA-B*08, DRB1*01, and DRB4), as well as Arg620Trp polymorphism in the PTPN22 gene are discussed as a cause of autoimmune diseases, including ASIA syndrome. AIM: To identify the presence of causative genetic factors in patients with ASIA syndrome by genetic screening, to identify adjuvants acting as a trigger, and to evaluate the efficacy of current therapy. MATERIALS AND METHODS: A single center observational study of 16 patients with ASIA syndrome and 10 controls was performed. Genetic screening was performed in 14 patients from the ASIA group and 10 patients from the control group. Further inclusion of patients in the study is planned. RESULTS: All patients with ASIA were women, potential triggers included hyaluronic acid fillers 10/16 (62.5 %), including in combination with breast silicone implants 1/16 (6.25 %), arthroplasty with shoulder joint replacement 1/16 (6.25 %), face hyaluronic acid injections 5/16 (31.25 %), and calcium hydroxyapatite 1/16 (6.25 %). The main site of angioedema was the face 15/16 (93.75 %), also larynx (1/16 (6.25 %)), upper (2/16) and lower extremities (1/16 (6,25 %)). Other symptoms included arthralgia, myalgia, muscle weakness — 1/16 (6.25%), hypocomplementemic urticarial vasculitis, lymphocytic colitis — 1/16 (6.25 %), arthralgia combined with lymphadenopathy — 1/16 (6.25 %), chronic spontaneous and solar urticaria — 1/16 (6.25 %), fixed erythema of the shoulder skin with fever, antiphospholipid syndrome — 1/16 (6.25 %), normocomplementemic urticarial vasculitis — 1/16 (6.25 %), Still’s disease — 1/16 (6.25 %). Autoimmune response was represented by autoantibodies in 10 (62.5 %) of 16 patients. Ten (62.5 %) patients received non-sedative antihistamines at standard and escalated doses (5 as monotherapy, 1 in combination with filler removal, 1 with hydroxychloroquine, 3 with hydroxychloroquine and omalizumab), 1 (6.25 %) received tranexamic acid, 1 (6.25 %) with danazol, 1 (6.25 %) with hydroxychloroquine, and 3 (18.75 %) patients received no therapy. A combination of two genetic factors was detected in 3 (21.4 %) patients: DRB1*0301, B1*08 (in 2 patients additionally Arg620Trp polymorphism). Isolated Arg620Trp polymorphism was detected in 6 (42.8 %) patients. CONCLUSION: Genetic factors increasing the risk of autoimmune conditions were found in 9 out of 16 patients. No genetic abnormalities were found in the control group. More than half of the patients with ASIA syndrome had genetic factors associated with autoimmunity. Further studies are needed to create reliable diagnostic and treatment algorithms.
- 25 November 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 277-280
Determination of the Temperature Threshold Value During Provocative Testing of Patients with Temperature Urticaria
The paper describes the results of using the TempPro temperature profiler developed at the Kotelnikov Institute of Radioengineering and Electronics of the Russian Academy of Sciences by order of the Center for Allergology and Immunology of State budgetary institution City Clinical Hospital No. 52 of the Moscow Department of Health. This hardware and software complex (HSC) is designed for provocative testing of patients with temperature urticaria, including its thermal and cold forms. In addition to fixing the very fact of the presence or absence of a specific biochemical reaction to the influence of an external temperature (thermal) factor, the technique developed by the authors provides the possibility of quantifying the intensity of the disease. This is achieved by measuring the threshold value of the temperature of external exposure at which the formation of a blister characteristic of urticaria begins in the case of a positive reaction to the tested variant of urticaria. The HSC is implemented in the form of an operating working layout with an appropriate basic set of software, and, unlike existing analogues, provides the possibility of selecting and subsequent monitoring by a diagnostic physician of the necessary temperature distribution along the linear applicator in the temperature range from +0 to +45 °C and exposure time from 1 to 20 minutes. The achieved accuracy of measuring the threshold temperature value is at least ± 0.5 °C. The report provides examples of the device's operation in various modes and the results of provocative effects on the skin of the studied patients.
- 25 November 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 277-280
Determination of the Temperature Threshold Value During Provocative Testing of Patients with Temperature Urticaria
The paper describes the results of using the TempPro temperature profiler developed at the Kotelnikov Institute of Radioengineering and Electronics of the Russian Academy of Sciences by order of the Center for Allergology and Immunology of State budgetary institution City Clinical Hospital No. 52 of the Moscow Department of Health. This hardware and software complex (HSC) is designed for provocative testing of patients with temperature urticaria, including its thermal and cold forms. In addition to fixing the very fact of the presence or absence of a specific biochemical reaction to the influence of an external temperature (thermal) factor, the technique developed by the authors provides the possibility of quantifying the intensity of the disease. This is achieved by measuring the threshold value of the temperature of external exposure at which the formation of a blister characteristic of urticaria begins in the case of a positive reaction to the tested variant of urticaria. The HSC is implemented in the form of an operating working layout with an appropriate basic set of software, and, unlike existing analogues, provides the possibility of selecting and subsequent monitoring by a diagnostic physician of the necessary temperature distribution along the linear applicator in the temperature range from +0 to +45 °C and exposure time from 1 to 20 minutes. The achieved accuracy of measuring the threshold temperature value is at least ± 0.5 °C. The report provides examples of the device's operation in various modes and the results of provocative effects on the skin of the studied patients.
- Open Access
- 16 June 2024
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 21 (2) , 216-229
New coronavirus infection SARS-CoV-2 in adult patients with inborn errors of immunity
BACKGROUND: Diagnosis and treatment of COVID-19 in patients with primary immunodeficiency, or inborn errors of immunity, are often challenging. AIM: Description of the COVID-19 course and therapy of adult patients with primary immunodeficiency treated in medical organizations of Moscow Healthcare Department. MATERIALS AND METHODS: We analyzed a cohort of 68 patients over 18 years (median ― 35 years) with primary immunodeficiency; 91% of patients have primary immunodeficiency with predominantly antibody deficiencies. Altogether 90 cases of the new СOVID-19 were analyzed: in 68 cases infection occurred for the first time, in 22 cases it recurred. The duration of the disease ranged from 3 to 80 days. Duration of PCR-positivity ranged from 0 to 59 days, median 8 days. RESULTS: Patients with Wuhan and Delta strains had more severe inflammatory signs according to C-reactive protein and lactate dehydrogenase, in patients with Wuhan lung involvement on CT-scam was larger. In demonstrated group of patients higher C-reactive protein correlated with larger lung involvement, longer duration of the disease and PCR-positivity, significant lymphopenia also correlated with higher C-reactive protein. To our data regularity of intravenous immunoglobulin therapy and IgG trough level didn’t correlate with infection severity and duration of the disease and virus-carriage. Indirectly, the change in the spectrum of medicine used in patients of the analyzed group coincided with the virus strain evolution. Anti-inflammatory therapy was mainly presented by dexamethasone and antagonists to interleukin 6 or its receptor (anti-IL-6): 55% and 73% for Wuhan, 63% and 50% for Delta, 17% and 39% for Omicron. Then, preference was gradually given to the target anti-cytokine medicine. Etiotropic antiviral therapy was more often used to treat infection caused by Wuhan and Delta strains ― 32% and 38%, respectively (in 17% for Omicron). With shifting toward immunotherapy by specific against COVID-19 immunoglobulins and monoclonal antibody to SARS-CoV-2: 5% and 9% for Wuhan, 0% and 75% for Delta, 48% and 83% for Omicron, respectively. Immune and etiotropic therapy was not carried out in Wuhan in 39%, in Delta in 43%, in Omicron in 41% of cases. The overall mortality rate from COVID-19 in the analyzed group was 3%. CONCLUSION: Patients with primary immunodeficiency represent a vulnerable group to the SARS-CoV-2 virus with a high risk of not only severe, but also a protracted and undulating course of infection, what must be taken into account for the correct interpretation of the patient's condition and the timely administration of the appropriate therapy.
- 16 June 2024
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 21 (2) , 216-229
Open AccessNew coronavirus infection SARS-CoV-2 in adult patients with inborn errors of immunity
BACKGROUND: Diagnosis and treatment of COVID-19 in patients with primary immunodeficiency, or inborn errors of immunity, are often challenging. AIM: Description of the COVID-19 course and therapy of adult patients with primary immunodeficiency treated in medical organizations of Moscow Healthcare Department. MATERIALS AND METHODS: We analyzed a cohort of 68 patients over 18 years (median ― 35 years) with primary immunodeficiency; 91% of patients have primary immunodeficiency with predominantly antibody deficiencies. Altogether 90 cases of the new СOVID-19 were analyzed: in 68 cases infection occurred for the first time, in 22 cases it recurred. The duration of the disease ranged from 3 to 80 days. Duration of PCR-positivity ranged from 0 to 59 days, median 8 days. RESULTS: Patients with Wuhan and Delta strains had more severe inflammatory signs according to C-reactive protein and lactate dehydrogenase, in patients with Wuhan lung involvement on CT-scam was larger. In demonstrated group of patients higher C-reactive protein correlated with larger lung involvement, longer duration of the disease and PCR-positivity, significant lymphopenia also correlated with higher C-reactive protein. To our data regularity of intravenous immunoglobulin therapy and IgG trough level didn’t correlate with infection severity and duration of the disease and virus-carriage. Indirectly, the change in the spectrum of medicine used in patients of the analyzed group coincided with the virus strain evolution. Anti-inflammatory therapy was mainly presented by dexamethasone and antagonists to interleukin 6 or its receptor (anti-IL-6): 55% and 73% for Wuhan, 63% and 50% for Delta, 17% and 39% for Omicron. Then, preference was gradually given to the target anti-cytokine medicine. Etiotropic antiviral therapy was more often used to treat infection caused by Wuhan and Delta strains ― 32% and 38%, respectively (in 17% for Omicron). With shifting toward immunotherapy by specific against COVID-19 immunoglobulins and monoclonal antibody to SARS-CoV-2: 5% and 9% for Wuhan, 0% and 75% for Delta, 48% and 83% for Omicron, respectively. Immune and etiotropic therapy was not carried out in Wuhan in 39%, in Delta in 43%, in Omicron in 41% of cases. The overall mortality rate from COVID-19 in the analyzed group was 3%. CONCLUSION: Patients with primary immunodeficiency represent a vulnerable group to the SARS-CoV-2 virus with a high risk of not only severe, but also a protracted and undulating course of infection, what must be taken into account for the correct interpretation of the patient's condition and the timely administration of the appropriate therapy.
- Open Access
- 15 April 2024
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 21 (1) , 98-111
Analysis of patients with cold urticaria in the context of typical and atypical forms
BACKGROUND: Cold urticaria is characterized by hives and/or angioedema and/or systemic reactions in response to a cold stimulus. Typical and atypical forms cold urticariahave distinguished features. Currently there is limited data in the literature on patients with isolated cold urticaria, as well as with typical and atypical forms. AIM: To analyze a cohort of patients with isolated cold urticaria and the characteristics of patients with typical and atypical cold urticaria. MATERIALS AND METHODS: We conducted a study of 89 patients with a verified diagnosis of cold urticaria, who underwent provocative testing (ice cube, TempTest). In case of a positive result, typical cold urticaria was diagnosed (n=38), negative ― atypical (n=51). The typical cold urticaria group was divided into 2 subgroups ― low threshold (17 degrees or less), high threshold (above 17 degrees). Correlations between characteristics in the subgroups were analyzed. Mathematical and statistical processing of the data was performed using the SPSS software package (version 22). Kraskell–Wallis and Dunn's criteria were used. For quantitative and categorical variables, dependence was assessed using Spearman correlation. RESULTS: The predominance of female gender, young age of disease onset, high prevalence of angioedema, high incidence of cold anaphylaxis, and atopy are noted in patients with cold urticaria. Most patients are on therapy with standard doses of antihistamines. Patients with atypical cold urticaria were younger (p=0.012), had earlier cold urticaria onset (p=0.003), lower basophil (p 0.001) and higher eosinophil counts (p=0.007). In the high temperature group, atypical cold urticaria was found to correlate with bronchial asthma (r=0.69; p 0.001) and the need to escalate the dose of antihistamines (r=0.4; p=0.03). It was also revealed that patients with cold anaphylaxis had lower scores on the Urticaria Control Test questionnaire (r=-0.46; p=0.03). At the same time, higher scores correlated in this group with the duration of the disease (r=0.66; p=0.001). In the low temperature threshold group, threshold correlates with female gender (r=-0.68; p=0.003), autoimmune diseases (r=0.51; p=0.043). Cold anaphylaxis correlates with angioedema (r=0.65; p=0.006) and autoimmune diseases (r=0.75; p=0.001). CONCLUSION: Cold anaphylaxis is a significant problem, especially in countries with cold climates. There are a number of factors that distinguish typical cold urticaria from atypical cold urticaria. Further research is needed on cold urticaria and the associated factors.
- 15 April 2024
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 21 (1) , 98-111
Open AccessAnalysis of patients with cold urticaria in the context of typical and atypical forms
BACKGROUND: Cold urticaria is characterized by hives and/or angioedema and/or systemic reactions in response to a cold stimulus. Typical and atypical forms cold urticariahave distinguished features. Currently there is limited data in the literature on patients with isolated cold urticaria, as well as with typical and atypical forms. AIM: To analyze a cohort of patients with isolated cold urticaria and the characteristics of patients with typical and atypical cold urticaria. MATERIALS AND METHODS: We conducted a study of 89 patients with a verified diagnosis of cold urticaria, who underwent provocative testing (ice cube, TempTest). In case of a positive result, typical cold urticaria was diagnosed (n=38), negative ― atypical (n=51). The typical cold urticaria group was divided into 2 subgroups ― low threshold (17 degrees or less), high threshold (above 17 degrees). Correlations between characteristics in the subgroups were analyzed. Mathematical and statistical processing of the data was performed using the SPSS software package (version 22). Kraskell–Wallis and Dunn's criteria were used. For quantitative and categorical variables, dependence was assessed using Spearman correlation. RESULTS: The predominance of female gender, young age of disease onset, high prevalence of angioedema, high incidence of cold anaphylaxis, and atopy are noted in patients with cold urticaria. Most patients are on therapy with standard doses of antihistamines. Patients with atypical cold urticaria were younger (p=0.012), had earlier cold urticaria onset (p=0.003), lower basophil (p 0.001) and higher eosinophil counts (p=0.007). In the high temperature group, atypical cold urticaria was found to correlate with bronchial asthma (r=0.69; p 0.001) and the need to escalate the dose of antihistamines (r=0.4; p=0.03). It was also revealed that patients with cold anaphylaxis had lower scores on the Urticaria Control Test questionnaire (r=-0.46; p=0.03). At the same time, higher scores correlated in this group with the duration of the disease (r=0.66; p=0.001). In the low temperature threshold group, threshold correlates with female gender (r=-0.68; p=0.003), autoimmune diseases (r=0.51; p=0.043). Cold anaphylaxis correlates with angioedema (r=0.65; p=0.006) and autoimmune diseases (r=0.75; p=0.001). CONCLUSION: Cold anaphylaxis is a significant problem, especially in countries with cold climates. There are a number of factors that distinguish typical cold urticaria from atypical cold urticaria. Further research is needed on cold urticaria and the associated factors.
- Open Access
- 20 September 2023
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 33 (5) , 623-632
Efficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression
The COronaVIrus Disease 2019 (COVID-19) is a common infectious disease characterized by hyperactivation of the immune response and the development of a “cytokine storm” upon progression. The aim of this study was to obtain additional information about the efficacy of the drug olokizumab in comparison with the Janus kinase inhibitor upadacitinib in real clinical practice in patients with mild to moderate COVID-19 and combined risk factors for disease progression. Methods. A single-center, non-interventional, prospective study was conducted in specialized day hospital patients (n = 125) who received therapy with olokizumab (n = 62) (64 mg once intravenously) and the Janus kinase inhibitor upadacitinib (n = 63) (orally, according to selected dosing regimen). The primary endpoint was the frequency of hospitalizations in the 24-hour hospital over the entire observation period. We also analyzed the frequencies of intensive care unit (ICU) transfer, prescription of respyratory therapy, use of “rescue” therapy (monoclonal antibodies/therapeutic proteins acting on interleukins (IL) and their receptors: IL-6 receptor inhibitors and Janus kinase inhibitors (baricitinib, tofacitinib, upadacitinib, etc.)), mortality, dynamics of laboratory and instrumental parameters, as well as frequency of negative and positive changes according to the clinical progression scale of the World Health Organization. Results. All study subjects showed rapid clinical improvement and recovery. Patients in both groups did not experience any negative clinical events, such as admission to a 24-hour hospital, prescription of respyratory therapy, use of “rescue” therapy, etc. Thus, the hyperinflammatory reaction and adverse clinical outcomes are effectively prevented by the timely use of both drugs. Those who received olokizumab had slightly higher levels of C-reactive protein (CRP) at baseline than those who received upadacitinib (p < 0.001). The median CRP value returned to normal on the 4th day in both groups. Patients treated with olokizumab showed a more pronounced change in CRP levels relative to baseline values. A similar trend was also established in body temperature. Conclusion. The study confirmed that early administration of olokizumab in patients with mild to moderate COVID-19 with several risk factors for the severe course is as effective a method of preemptive anti-inflammatory therapy as the use of Janus kinase inhibitors but more stronger suppression of markers and symptoms of intoxication.
- 20 September 2023
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 33 (5) , 623-632
Open AccessEfficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression
The COronaVIrus Disease 2019 (COVID-19) is a common infectious disease characterized by hyperactivation of the immune response and the development of a “cytokine storm” upon progression. The aim of this study was to obtain additional information about the efficacy of the drug olokizumab in comparison with the Janus kinase inhibitor upadacitinib in real clinical practice in patients with mild to moderate COVID-19 and combined risk factors for disease progression. Methods. A single-center, non-interventional, prospective study was conducted in specialized day hospital patients (n = 125) who received therapy with olokizumab (n = 62) (64 mg once intravenously) and the Janus kinase inhibitor upadacitinib (n = 63) (orally, according to selected dosing regimen). The primary endpoint was the frequency of hospitalizations in the 24-hour hospital over the entire observation period. We also analyzed the frequencies of intensive care unit (ICU) transfer, prescription of respyratory therapy, use of “rescue” therapy (monoclonal antibodies/therapeutic proteins acting on interleukins (IL) and their receptors: IL-6 receptor inhibitors and Janus kinase inhibitors (baricitinib, tofacitinib, upadacitinib, etc.)), mortality, dynamics of laboratory and instrumental parameters, as well as frequency of negative and positive changes according to the clinical progression scale of the World Health Organization. Results. All study subjects showed rapid clinical improvement and recovery. Patients in both groups did not experience any negative clinical events, such as admission to a 24-hour hospital, prescription of respyratory therapy, use of “rescue” therapy, etc. Thus, the hyperinflammatory reaction and adverse clinical outcomes are effectively prevented by the timely use of both drugs. Those who received olokizumab had slightly higher levels of C-reactive protein (CRP) at baseline than those who received upadacitinib (p < 0.001). The median CRP value returned to normal on the 4th day in both groups. Patients treated with olokizumab showed a more pronounced change in CRP levels relative to baseline values. A similar trend was also established in body temperature. Conclusion. The study confirmed that early administration of olokizumab in patients with mild to moderate COVID-19 with several risk factors for the severe course is as effective a method of preemptive anti-inflammatory therapy as the use of Janus kinase inhibitors but more stronger suppression of markers and symptoms of intoxication.
- Open Access
- 29 June 2023
- Published by Wiley
Photoplethysmography for non-invasive diagnosis of cold urticaria
Background: Cold urticaria (ColdU) is a common type of chronic inducible urticaria. Patients with typical ColdU develop wheals in response to standard cold stimulation tests (CSTs), an ice cube (ICT) or TempTest ® . As of now, the evaluation of CST response is visual and subjective. Validated, robust, and objective test readouts lacking today are needed. Methods: We subjected 63 patients (39 with typical ColdU and 24 with atypical ColdU) and 15 healthy controls (HCs) to TempTest ® CSTs and critical temperature threshold assessments. Blood microcirculation photoplethysmography (PPG) measurements were performed 5 min before and 10 min after the ICT on the volar forearm. Results: PPG amplitudes reflected normal baseline skin blood perfusion in patients with typical or atypical ColdU. Ice cube CSTs induced a marked increase in blood perfusion and PPG amplitudes in typical but not atypical ColdU, with distinct pre-post CST changes in PPG amplitudes in the former. The ratio of post-provocation and baseline PPG amplitudes ( R PPG ) in typical ColdU patients exceeded that in atypical ColdU patients and HCs more than 3-fold. Almost all typical ColdU patients (98%), but only 13% of atypical ColdU patients and 7% of HCs had R PPG >3. PPG results matched those of CSTs in 94% of all tested individuals. Conclusion: Photoplethysmographic assessments of CST responses appear accurate and provide objective readouts. PPG may be of use in diagnosing ColdU, distinguishing typical and atypical ColdU, and more precise threshold testing.
- 29 June 2023
- Published by Wiley
Open AccessPhotoplethysmography for non-invasive diagnosis of cold urticaria
Background: Cold urticaria (ColdU) is a common type of chronic inducible urticaria. Patients with typical ColdU develop wheals in response to standard cold stimulation tests (CSTs), an ice cube (ICT) or TempTest ® . As of now, the evaluation of CST response is visual and subjective. Validated, robust, and objective test readouts lacking today are needed. Methods: We subjected 63 patients (39 with typical ColdU and 24 with atypical ColdU) and 15 healthy controls (HCs) to TempTest ® CSTs and critical temperature threshold assessments. Blood microcirculation photoplethysmography (PPG) measurements were performed 5 min before and 10 min after the ICT on the volar forearm. Results: PPG amplitudes reflected normal baseline skin blood perfusion in patients with typical or atypical ColdU. Ice cube CSTs induced a marked increase in blood perfusion and PPG amplitudes in typical but not atypical ColdU, with distinct pre-post CST changes in PPG amplitudes in the former. The ratio of post-provocation and baseline PPG amplitudes ( R PPG ) in typical ColdU patients exceeded that in atypical ColdU patients and HCs more than 3-fold. Almost all typical ColdU patients (98%), but only 13% of atypical ColdU patients and 7% of HCs had R PPG >3. PPG results matched those of CSTs in 94% of all tested individuals. Conclusion: Photoplethysmographic assessments of CST responses appear accurate and provide objective readouts. PPG may be of use in diagnosing ColdU, distinguishing typical and atypical ColdU, and more precise threshold testing.
- Open Access
- 24 February 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (1) , 78-84
Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim. To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and methods. Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results. In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p0.001). Conclusion. The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.
- 24 February 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (1) , 78-84
Open AccessPre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim. To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and methods. Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results. In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p0.001). Conclusion. The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.